Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434608 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL8843134 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL15434693 | 0.81 | PAOX (0.42) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL25056684 | 0.77 | MEN1 (0.47) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL12463688 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL16940044 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL28884585 | 0.75 | ARG1 (0.55) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL15434663 | 0.74 | ALDH1A1 (0.48) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL16940028 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2AGLAOPRM1 | |
| SCHEMBL126548 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2AGLAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-20210130821-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-06 | — | — | US | disclosed |
| US-10590413-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-17 | — | — | US | disclosed |
| US-9982257-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9885037-B2 | — | — | 2018-02-06 | — | — | US | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130821-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
| US-10590413-B2 | Chiral control | RNGTT, POLI, NSUN3 | SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.